Skip to main content
OpenTrials
Completed

NCT Number: NCT01956019

MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study

This study will use diffusion weighted MRI (DWI MRI) and dynamic-contrast enhanced MRI (DCE MRI) techniques to detect changes in sarcoma tumour vasculature. The main aims of this study are to correlate histological response of soft tissue sarcoma after pre-operative radiotherapy with several pre-treatment DCE and DWI MRI parameters and to assess the impact of these on early response prediction. Detected changes may reflect the sensitivity of the tumour to radiotherapy and may be associated with long term outcomes after treatment.

15 patients normally having pre-operative radiotherapy as part of their sarcoma treatment will be recruited to this study.

Patients will have an additional three specialised MRI scans: one prior to the start of radiotherapy, one during the second week of radiotherapy while on treatment and one scan a week before surgery but after the completion of radiotherapy.

Post-operatively, results of the histological examination of the sarcoma will be correlated to both the MRI scan data and outcomes after treatment

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoma Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have histologically confirmed diagnosis of intermediate/high grade soft tissue sarcoma (STS)
  • Patients must be suitable for treatment with preoperative radiotherapy and radical surgery
  • Standard radiological assessments (CT or MRI) may have already been performed but must be done within 4 weeks of starting radiotherapy
  • Patient must have measurable disease on CT/MRI imaging
  • ECOG performance status 0-2
  • Adequate pre-treatment haematological and biochemical parameters
  • Age greater than or equal to 18 years
  • No significant co-morbidity thereby excluding patient from having radical treatment.
  • No previous treatment for diagnosis of STS including neo-adjuvant chemotherapy
  • Women of child bearing age MUST have a negative pregnancy test prior to study entry and be using an adequate contraception method unless child bearing potential has been terminated by surgery/radical radiotherapy
  • Patients must have given written informed consent

Exclusion criteria

  • Patients with cardiac pacemakers, cochlear implants, intraocular foreign bodies or any other MRI incompatibility factors (e.g. recent surgery).
  • Patients with a known history of anaphylactic reaction to contrast material for MRI
  • Previous administration of gadoxetic acid or other contrast material 24hr prior to or after the MRI
  • Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial
  • Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial
  • Any other serious uncontrolled medical conditions
  • Clinical evidence of metastatic disease
  • Any pregnant or lactating woman
  • Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
  • Evidence of impaired renal function, serum creatinine >1.5x upper limit of normal

Treatment and study plan

MRI scanning

Device

Primary outcomes

  1. Correlate histological response of soft tissue sarcoma after pre-operative radiotherapy with pre-treatment DWI and DCE-MRI parameters.

    Time frame: average of 9 weeks including radiotherapy up to one week before surgery

    The hypothesis is that quantitative biomarkers from DWI and DCE MRI can not only be produced with high spatial resolution in soft tissue sarcoma, but that these imaging biomarkers will correlate with histological and histochemical features of the tumour and will provide information to support the prediction of regional response to radiotherapy.

Secondary outcomes

  1. early response prediction of treatment using functional parameters of in-treatment imaging with DWI and DCE-MRI (e.g. relative change in apparent diffusion coefficient values)

    Time frame: following surgery at week 7

  2. accuracy of outlining treatment volumes using STIR. T1W, T2W and DWI MRI compared to standard planning CT and loco-regional control patterns

    Time frame: 3 month follow up visit

  3. local recurrence patterns with pre-treatment functional MRI.

    Time frame: 3 timepoints for scans over 6 weeks of treatment

    Within our study, these patients would have an additional three specialised MRI scans: one prior to the start of radiotherapy, one during the second week of radiotherapy while on treatment and one scan the week before the operation after the completion of radiotherapy

Sponsors and collaborators

Lead sponsor

The Christie NHS Foundation Trust

Other

Registry information

Official study title

Feasibility Study to Compare Early Response Assessment and Planning Volumes With Contrast-enhanced Computed Tomography (CT), MRI Including Diffusion Weighted MRI (DWI) and Dynamic-contrast Enhanced (DCE) MRI in Patients With Limb Sarcoma Undergoing Pre-operative Radiotherapy

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Oct 8, 2013
Registry last updated
Apr 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.